Clinical Trial

Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2025 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
In operating procedure with general anesthesia muscle relaxant is usually used to increase success rate of the operation and to give better outcome. The use of reversal drugs aims to reduce the risk of post-operative complications due to muscle relaxants. Neostigmine is commonly used as a reversal drug, but its indirect mechanism of action results in a long and unpredictable recovery time. Sugammadex directly bind and inactivate rocuronium, in which resulting in a faster and predictable recovery time. However, the high price limits the use of sugammadex. This study aims to compare the effect of half dose sugammadex and neostigmine against the moderate neuromuscular blockade of rocuronium. The main questions it aims to answer are: Does half dose sugammadex gives faster recovery time? Researchers will compare sugammadex to neostigmine to see if sugammadex gives faster recovery time. Participants will: Be given sugammadex or neostigmine as a reversal drug after the operation done
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-20.
Trial Details
NCT Number NCT06794450
Lead Sponsor Universitas Padjadjaran
Conditions Neuromuscular Blocking Agents, Reversal of Neuromuscular Blockade, Recovery Time
Enrollment 60 participants
Start Date 2024-11-05
Primary Completion 2025-02 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2025-01-28